"一妇婴对宫颈癌防治方面的整体策略和定位是什么？" "公众对宫颈癌最大的误区是什么？" 宫颈癌是威胁女性健康的重大疾病，近年来发病率持续上升，而且呈现年轻化的趋势。作为全国宫颈癌 防治的重要力量，上海市第一妇婴保健院在HPV疫苗接种推广、精准筛查、个性化治疗等方面探索出了 一条全链条诊治路径。本期节目，我们特别邀请到一妇婴副院长王薇教授和宫颈疾病中心主任浦筱雯医 生，请她们分享一妇婴在宫颈癌防治领域的创新实践与前沿探索。 "AI技术在一妇婴的宫颈癌筛查的精准诊断中扮演什么样的角色？" 本期节目，我们将回答： 1月10日周六8:30 新闻综合频道&看看新闻客户端 ...

本次培训生动诠释了中国第35批援桑给巴尔医疗队对"为当地留下带不走的医疗队"理念的贯彻坚 持，有望大幅提升桑给巴尔当地妇科医生在宫颈癌防治领域的专业水平。未来，医疗队将进一步深化与 当地医疗卫生领域的合作，推动中非卫生健康合作不断深入，为构建人类卫生健康共同体贡献中国力 量。 此次授课紧贴桑给巴尔当地医疗需求，聚焦宫颈癌防治的全过程。首日，韩利伟结合全球宫颈癌防 治最新趋势及临床经验，对该领域前沿技术、综合治疗新路径进行了全面的讲解。次日，刘慧玲针对临 床实操中的难点，重点分享了宫颈癌精准防控的典型案例、核心技能与关键流程，为当地医生提供了具 像化、可借鉴的实践范本。 培训现场互动氛围热烈。桑给巴尔本地医生围绕筛查技术本土化应用、特殊人群诊疗策略等实际工 作痛点踊跃提问，展现出对先进医疗知识的迫切需求。对此，两位专家通过理论讲解与案例分享，为参 会医生逐一解答、理清困惑，助力培训内容落地转化。桑给巴尔卫生部国际卫生健康合作处负责人哈蒂 迦女士表示，医疗队的培训内容兼具前沿性与实用性，为当地宫颈癌防治工作提供了全新思路。 人民网约翰内斯堡11月27日电 （记者邹松、实习生董嘉怡）由中国商务部主办、国家卫生健康委 ...

Group 1 - The 13th China Cervical Cancer Prevention Engineering Academic Annual Conference was held in Shanghai, focusing on key issues such as cervical cancer prevention, basic research, HPV vaccines, screening, and treatment [1][2] - The conference theme was "Precise Prevention and Treatment, Integrated Innovation - Accelerating the Elimination of Cervical Cancer," aiming to enhance gynecological diagnosis and treatment levels in grassroots medical institutions [2][3] - The "90-70-90" cervical cancer prevention target was highlighted, indicating the need for continued efforts to explore optimal prevention paths suitable for China's national conditions [2][3] Group 2 - The Pat Bio Group, a subsidiary of Pat Ling, won the "Social Responsibility Award" at the conference, marking its continuous recognition for over thirty years in the field [1][3] - The conference served as a significant platform for summarizing and exchanging annual viewpoints on cervical cancer and HPV prevention, linking social and medical forces, and integrating advantages from different disciplines [3] - Emphasis was placed on breaking down disciplinary barriers and fostering innovative concepts in cervical cancer prevention, aligning with technological advancements [3]

Core Viewpoint - The launch of China's first domestically produced nine-valent HPV vaccine "Xinkening®9" at a price of 499 yuan per dose significantly undercuts the imported vaccine priced at 1300 yuan, marking the end of the "high-price era" for HPV vaccines [1] Group 1: Product Pricing and Market Impact - The domestic nine-valent HPV vaccine is priced at approximately 40% of the imported vaccine's market standard price [1] - The competitive pricing is expected to enhance the willingness of eligible women to get vaccinated, contributing to the establishment of a national immunity barrier and accelerating the goal of cervical cancer elimination [1] - The pricing strategy is projected to benefit over 100 million women in China and positively impact global cervical cancer prevention efforts [1] Group 2: Company Initiatives and Global Expansion - After the approval of the nine-valent HPV vaccine, the company is actively advancing the national bidding and procurement process as per its established plan [1] - The company is also working diligently on the WHOPQ certification process for the nine-valent HPV vaccine, leveraging its international achievements with the two-valent HPV vaccine, which has gained market access in over 20 countries and is included in the immunization programs of 8 countries [1] - The company expresses confidence in accelerating the overseas access and expansion of the nine-valent HPV vaccine through its established global network [1]

Group 1 - The trend of HPV infections is increasingly affecting younger populations, challenging the perception that HPV is primarily a concern for older individuals [1][4][6] - Studies indicate that cervical cancer incidence is rising among women aged 25-45, particularly among those born in the 1980s and 1990s, with a notable peak in HPV infections occurring between the ages of 17-24 [4][6] - The prevalence of HPV infections among young males also shows a dual peak distribution, with infection rates of 47.6% for ages 18-24 and 44.51% for ages 40-44, highlighting a significant transmission risk [4][6] Group 2 - Experts recommend proactive measures such as vaccination, regular screenings, and maintaining a healthy lifestyle to enhance immunity against HPV [6][7] - It is emphasized that HPV infection does not equate to disease, and there is no need for excessive fear regarding HPV [7] - Traditional Chinese medicine, including herbal formulations, is suggested as a viable intervention for HPV infections, providing alternatives for those apprehensive about surgical options [6][7]

Group 1 - The core initiative is the implementation of a subsidized HPV vaccination program in Shaanxi Province, aimed at increasing vaccine accessibility and uptake among women aged 9 to 45 [1][2] - The program will run from May 20, 2025, to April 30, 2026, and is designed to promote cervical cancer prevention through HPV vaccination [1] - Eligible individuals who receive their first or second dose of the HPV vaccine during the program will benefit from reduced vaccination costs, only paying for the service fee [1][2] Group 2 - The program includes three types of HPV vaccines: bivalent, quadrivalent, and nonavalent, with a total of five vaccine options available [1] - A specific timeline is established where individuals must receive their first dose by September 30, 2025, to qualify for the subsidy [2] - An online registration system via the "Healthy Shaanxi Public Service" WeChat mini-program will be available from May 20, 2025, to facilitate appointment scheduling for vaccinations [2]